Last Price$523.6(1.0%)
Market Cap$201.0B
P/EBITDA LTM
17.5x
5Y avg
18.8x
Medical - Diagnostics & Research industry
median
(0.7x)
Stock quality & Intrinsic value
6/10
0.2% undervalued
Thermo Fisher Scientific Inc. P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | 21.4x | 13.5x | 40.0x | 16.7x | 6.9x | 10.6x | 11.1x | 8.1x | 9.2x | 15.4x | 14.0x | 14.2x | 12.7x | 16.0x | 15.0x | 20.1x | 21.9x | 19.8x | 17.2x | 18.8x |
Overvalued or undervalued?
Check the intrinsic value for TMO
and see if it's the right time to invest.
Thermo Fisher Scientific Inc. (TMO) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Thermo Fisher Scientific Inc.TMO
19.2x
(4.6%)
(12.4%)
14.0%
Median Peer Set
21.9x
(0.1%)
2.4%
16.3%
IDEXX Laboratories, Inc.IDXX
29.2x
8.7%
25.2%
23.1%
Waters CorporationWAT
22.5x
(0.5%)
(7.9%)
21.7%
Danaher CorporationDHR
22.4x
(0.1%)
(17.9%)
16.3%
Agilent Technologies, Inc.A
22.1x
(4.7%)
5.0%
19.8%
Mettler-Toledo International Inc.MTD
21.9x
2.2%
12.7%
22.3%
Quest Diagnostics IncorporatedDGX
11.2x
(6.4%)
(6.5%)
9.2%
IQVIA Holdings Inc.IQV
9.9x
2.8%
2.4%
8.9%
Illumina, Inc.ILMN
(16.6x)
(2.9%)
4.6%
(28.0%)
Natera, Inc.NTRA
(113.7x)
32.0%
(32.1%)
(40.2%)
TMO key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 2,206.0 0.0% | 2,633.0 19.4% | 3,791.6 44.0% | 9,746.4 157.1% | 10,498.0 7.7% | 10,109.7 (3.7%) | 10,788.7 6.7% | 11,725.9 8.7% | 12,509.9 6.7% | 13,090.3 4.6% | 16,889.6 29.0% | 16,965.4 0.4% | 18,274.1 7.7% | 20,918.0 14.5% | 24,358.0 16.4% | 25,542.0 4.9% | 32,218.0 26.1% | 39,211.0 21.7% | 44,915.0 14.5% | 42,857.0 (4.6%) |
| Cost of Goods Sold (COGS) | 1,191.5 | 1,438.1 | 2,223.6 | 5,942.0 | 6,291.8 | 5,960.3 | 6,215.1 | 6,737.3 | 6,993.0 | 7,339.2 | 8,970.6 | 8,782.7 | 9,459.1 | 10,961.0 | 12,994.0 | 13,715.0 | 15,713.0 | 18,977.0 | 25,415.0 | 25,744.0 |
% margin | 1,014.5 46.0% | 1,194.9 45.4% | 1,568.1 41.4% | 3,804.4 39.0% | 4,206.2 40.1% | 4,149.4 41.0% | 4,573.6 42.4% | 4,988.6 42.5% | 5,516.9 44.1% | 5,751.1 43.9% | 7,919.0 46.9% | 8,182.7 48.2% | 8,815.0 48.2% | 9,957.0 47.6% | 11,364.0 46.7% | 11,827.0 46.3% | 16,505.0 51.2% | 20,234.0 51.6% | 19,500.0 43.4% | 17,113.0 39.9% |
| Operating Expenses | 761.1 | 914.6 | 1,280.4 | 2,787.8 | 2,941.4 | 3,039.7 | 3,248.3 | 3,643.0 | 3,952.7 | 4,063.8 | 6,014.2 | 5,731.2 | 6,176.6 | 6,892.0 | 7,531.0 | 7,646.0 | 8,612.0 | 10,009.0 | 10,993.0 | 10,254.0 |
| Research & Development Expenses (R&D) | 134.7 | 152.8 | 170.2 | 238.7 | 249.1 | 246.1 | 287.2 | 340.6 | 376.4 | 395.5 | 691.1 | 692.3 | 754.8 | 888.0 | 967.0 | 1,003.0 | 1,181.0 | 1,406.0 | 1,471.0 | 1,337.0 |
| Selling, General & Administrative Expenses (SG&A) | 626.5 | 761.8 | 1,110.2 | 2,549.1 | 2,692.3 | 2,196.6 | 2,389.4 | 2,654.5 | 2,828.7 | 2,905.2 | 3,991.4 | 3,724.1 | 4,043.8 | 4,410.0 | 4,823.0 | 4,930.0 | 5,764.0 | 6,842.0 | 7,127.0 | 8,445.0 |
% margin | 237.5 10.8% | 263.5 10.0% | 242.0 6.4% | 974.4 10.0% | 1,229.4 11.7% | 1,048.9 10.4% | 1,264.9 11.7% | 1,245.2 10.6% | 1,482.1 11.8% | 1,609.6 12.3% | 2,503.0 14.8% | 2,336.2 13.8% | 2,449.2 13.4% | 2,968.0 14.2% | 3,783.0 15.5% | 4,594.0 18.0% | 7,794.0 24.2% | 10,028.0 25.6% | 8,393.0 18.7% | 6,859.0 16.0% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 51.7 | 16.1 | 12.5 | 26.9 | 25.2 | 28.0 | 47.7 | 30.6 | 48.4 | 81.0 | 137.0 | 224.0 | 65.0 | 43.0 | 272.0 | 879.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 151.5 | 118.1 | 84.7 | 175.3 | 241.6 | 262.1 | 479.9 | 414.9 | 469.6 | 592.0 | 667.0 | 676.0 | 553.0 | 536.0 | 726.0 | 1,375.0 |
| Pre-tax Income | 259.2 | 285.9 | 209.4 | 881.3 | 1,149.6 | 927.1 | 1,164.6 | 1,126.6 | 1,269.4 | 1,319.5 | 2,087.2 | 1,936.4 | 2,023.9 | 2,429.0 | 3,262.0 | 4,070.0 | 7,225.0 | 8,841.0 | 7,835.0 | 6,298.0 |
% effective tax rate | 40.9 15.8% | 87.6 30.6% | 43.1 20.6% | 101.7 11.5% | 160.9 14.0% | 75.8 8.2% | 131.5 11.3% | 107.0 9.5% | 11.0 0.9% | 40.4 3.1% | 191.7 9.2% | (43.9) (2.3%) | (1.4) (0.1%) | 201.0 8.3% | 324.0 9.9% | 374.0 9.2% | 850.0 11.8% | 1,109.0 12.5% | 703.0 9.0% | 284.0 4.5% |
% margin | 361.8 16.4% | 223.2 8.5% | 168.9 4.5% | 761.1 7.8% | 994.2 9.5% | 850.3 8.4% | 1,035.6 9.6% | 1,329.9 11.3% | 1,177.9 9.4% | 1,273.3 9.7% | 1,894.4 11.2% | 1,975.4 11.6% | 2,021.8 11.1% | 2,225.0 10.6% | 2,938.0 12.1% | 3,696.0 14.5% | 6,375.0 19.8% | 7,725.0 19.7% | 6,950.0 15.5% | 5,995.0 14.0% |
| EPS | 2.22 | 1.38 | 0.86 | 1.81 | 2.34 | 2.06 | 2.57 | 3.49 | 3.24 | 3.53 | 4.76 | 4.96 | 5.12 | 5.64 | 7.31 | 9.24 | 16.10 | 19.61 | 17.73 | 15.53 |
| Diluted EPS | 2.17 | 1.36 | 0.84 | 1.72 | 2.25 | 2.01 | 2.53 | 3.46 | 3.21 | 3.48 | 4.71 | 4.92 | 5.09 | 5.59 | 7.24 | 9.17 | 15.98 | 19.46 | 17.64 | 15.45 |
% margin | 336.3 15.2% | 435.9 16.6% | 502.1 13.2% | 1,777.9 18.2% | 2,072.2 19.7% | 1,832.5 18.1% | 1,912.1 17.7% | 2,184.2 18.6% | 2,494.7 19.9% | 2,581.7 19.7% | 4,251.9 25.2% | 4,039.5 23.8% | 4,251.5 23.3% | 5,254.0 25.1% | 6,195.0 25.4% | 6,463.0 25.3% | 10,192.0 31.6% | 12,964.0 33.1% | 11,941.0 26.6% | 11,079.0 25.9% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Thermo Fisher Scientific Inc.'s P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 17.5x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBITDA LTM for Thermo Fisher Scientific Inc. have been 18.2x over the past three years, and 19.7x over the past five years.
2) Is Thermo Fisher Scientific Inc.'s P/EBITDA LTM Good?
As of today, Thermo Fisher Scientific Inc.'s P/EBITDA LTM is 17.5x, which is higher than industry median of (0.7x). It indicates that Thermo Fisher Scientific Inc.'s P/EBITDA LTM is Bad.